Vaccine Info

Delta gD-2 (∆gD-2) Herpes Vaccine

Authored by
Last reviewed
March 6, 2021

Delta gD-2 (∆gD-2) Herpes Vaccine Description

The Delta gD-2 (∆gD-2) herpes vaccine candidate elicits antibodies that facilitate the killing of infected cells, which then rapidly clears the HSV-1 and HSV-2 viruses.

∆gD-2 acts via a novel mechanism of action mediated by non-neutralizing, Fc receptor activating antibodies to prevent both HSV-1 and HSV-2 infection with a wide range of clinical and laboratory isolates. The broad protection observed in a variety of pre-clinical models combined with the potential for sterilizing immunity, as evidenced by the absence of latent virus, supports the clinical development of ∆gD-2, says X-Vax Technology, Inc.

The vaccine induces Fc receptor activating antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) as the primary protection mechanism. ADCC is induced to flag infected cells for destruction by natural immune cells.

'We have created a herpes vaccine candidate that we call ∆gD-2 (delta gD-2) because it is based on an HSV-2 virus genetically deleted for glycoprotein D (gD-2). With it, we have been able to prevent infections caused by herpes type 1 (HSV-1) and type 2 (HSV-2) in multiple preclinical models—with encouraging results,' says the company.

X-Vax Technology, Inc. is a biotech company committed to developing vaccines against pathogens acquired by a mucosal infection such as herpes. Our research leads us to believe that the new approach we are taking could succeed in defeating herpes.

Delta gD-2 (∆gD-2) Herpes Vaccine Indication

The ∆gD-2 Herpes Vaccine candidate is indicated to clear the virus as well as prevent latency.  Latency is a non-replicating state that periodically will reactivate, resulting in lifelong infection and the ongoing risk of shedding the virus to others.

Delta gD-2 (∆gD-2) Herpes Vaccine News

November 6, 2020 - Study: The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model.

July 17, 2020 - Florida based X-Vax Technology, Inc. announced Isaac Blech's appointment as Vice Chairman of the company's board of directors. As a co-founder of X-VAX, Mr. Blech previously served on the company's Board until December 2019.

June 16, 2020 - A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.

October 10, 2019 - Murine Model of Maternal Immunization Demonstrates Protective Role for Antibodies That Mediate Antibody-Dependent Cellular Cytotoxicity in Protecting Neonates From Herpes Simplex Virus Type 1 & Type 2.

October 3, 2019 - X-Vax believes the key to immunity against HSV is to prevent new virion production and release by killing infected cells. Its lead vaccine, ΔgD-2, elicits non-neutralizing antibodies that trigger antibody-dependent cellular cytotoxicity (ADCC)

July 23, 2019: Proceeds from the $56 million Series A financing will be used to advance X-VAX's lead program, a vaccine candidate against herpes called ∆gD-2 (delta gD-2) for further development and production, including a Phase 1 clinical study. "We believe that ∆gD-2 may be more promising than other previous vaccine candidates because it elicits a different type of immune response against HSV-1 and HSV-2 that is more effective in preclinical models at clearing virus and preventing the establishment of latency. In nonclinical models, immunization with ∆gD-2 elicits antibodies that facilitate the killing of infected cells, rapidly clearing the virus and thereby inducing sterilizing immunity," added William Jacobs, Ph.D., co-Inventor and Professor of Microbiology & Immunology at Albert Einstein College of Medicine.

August 4, 2016 - HSV-2 ΔgD elicits FcγR-effector antibodies that protect against clinical isolates.

Clinical Trials

No clinical trials found